Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will rep...
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks1Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations Bagsværd, Denmark, 23 February 2026 – Novo Nordisk today announced headline results from REDEFINE 4, an open-label ph...
Earlier this month, Ahold Delhaize reported strong 4Q25 results, driven by a material margin beat in the US and impressive free cash flow generation. While the 2026 margin outlook was in line with expectations, we believe the company is well positioned to deliver on this guidance supported by the impact of the 53rd calendar week, easier comparables in Europe, and the gradual realisation of synergies from the Profi acquisition. In the US, ongoing price investments continue to drive healthy sales ...
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, entrance 6, 2300 Copenhagen S, Denmark, or virtually by PC or smartphone/tablet. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual Gen...
Ahold Delhaize: Peer Walmart 4Q25/26 results. Arcadis: Main topics 4Q25/FY25 conference call. ASM: 4Q25 preview, FY26 should be strong. Brunel: 4Q25 result beats and trends stabilise; DACH back to growth in 1Q26; additional cost savings announced and special dividend. Cofinimmo: Beat on bottom line, strong investment outlook for 2026. IMCD: Another step in EMEA. Magnum Ice Cream Company: Peer Danone 4Q25 results. Recticel: Peer Kingspan FY25 results. Software sector: Cheaper code...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will rep...
A director at Voestalpine AG sold 517 shares at 44.220EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...
Designated person notification 11 February 2026, 16:30 CET With reference to Article 19(3) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulations), ArcelorMittal announces that notification of share transaction by a Designated Person (i.e. Directors or Executive Officers) is available in the Luxembourg Stock Exchange’s electronic database OAM on and on ArcelorMittal’s web site under Investors > Share Transactions by Management: ENDS About ArcelorMittal ArcelorMittal is one of the world’s leading integrat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.